# A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

> **NCT01994057** · — · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 1000 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- EGFR-TKI Resistant Mutation
- EGFR-TKI Sensitizing Mutation
- Germline Mutations
- Somatic Mutation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01994057
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2012-09
- **Primary completion:** 2025-10
- **Final completion:** 2026-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01994057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01994057, "A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01994057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*